Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
(Amendment No. 1)*
|
Eupraxia Pharmaceuticals Inc. (Name of Issuer) |
Common Shares, with no par value (Title of Class of Securities) |
29842P105 (CUSIP Number) |
09/30/2025 (Date of Event Which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
 Rule 13d-1(b)
|
| Rule 13d-1(c)
|
 Rule 13d-1(d)
|
SCHEDULE 13G
|
| CUSIP No. | 29842P105 |
| 1 | Names of Reporting Persons
Robert Disbrow | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CANADA (FEDERAL LEVEL)
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
3,568,150.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
7 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person: (1) Rows 7, 9 and 11 includes (a) 3,068,150 shares of the Issuer's (as defined below) common shares, with no par value (the "Common Shares") and 200,000 Common Shares underlying Issuer's Series 1 preferred shares, with no par value (the "Preferred Shares") jointly owned by Robert Disbrow and Kim Kawaguchi, husband and wife (the "Disbrows"); and (b) 300,000 Common Shares held by the children of the Disbrows. The Disbrows disclaim beneficial ownership of the Common Shares held by their children. (2) Row 13 is calculated based on the Common Shares and Preferred Shares, beneficially owned by the Reporting Person relative to the Issuer's 50,598,331 outstanding Common Shares, as of September 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on November 4, 2025, plus the 200,000 Preferred Shares.
SCHEDULE 13G
|
| Item 1. | |
| (a) | Name of issuer:
Eupraxia Pharmaceuticals Inc. |
| (b) | Address of issuer's principal executive offices:
201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada, V8R 5GR |
| Item 2. | |
| (a) | Name of person filing:
This Schedule 13G is being filed by Robert Disbrow (the "Reporting Person"). |
| (b) | Address or principal business office or, if none, residence:
200 Burrard Street, Suite 700, Vancouver, BC V6C 3L6 |
| (c) | Citizenship:
Canada |
| (d) | Title of class of securities:
Common Shares, with no par value |
| (e) | CUSIP No.:
29842P105 |
| Item 4. | Ownership |
| (a) | Amount beneficially owned:
3,568,150 |
| (b) | Percent of class:
7.0 %
|
| (c) | Number of shares as to which the person has:
|
| (i) Sole power to vote or to direct the vote:
0 | |
| (ii) Shared power to vote or to direct the vote:
3,568,150 | |
| (iii) Sole power to dispose or to direct the disposition of:
0 | |
| (iv) Shared power to dispose or to direct the disposition of:
3,568,150 | |
| Item 5. | Ownership of 5 Percent or Less of a Class. |
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. |
Not Applicable
| |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
Not Applicable
| |
| Item 8. | Identification and Classification of Members of the Group. |
Not Applicable
| |
| Item 9. | Notice of Dissolution of Group. |
Not Applicable
|
| Item 10. | Certifications: |
Not Applicable
|
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|